This is a Validated Antibody Database (VAD) review about dog ERBB3, based on 31 published articles (read how Labome selects the articles), using ERBB3 antibody in all methods. It is aimed to help Labome visitors find the most suited ERBB3 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
ERBB3 synonym: receptor tyrosine-protein kinase erbB-3; LOW QUALITY PROTEIN: receptor tyrosine-protein kinase erbB-3; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3; v-erb-b2 erythroblastic leukemia viral oncogene homolog 3

Cell Signaling Technology
rabbit monoclonal (21D3)
  • western blot; human; 1:500; loading ...; fig 4b
Cell Signaling Technology ERBB3 antibody (Cell Signaling Technologies, 4791) was used in western blot on human samples at 1:500 (fig 4b). elife (2019) ncbi
rabbit monoclonal (21D3)
  • western blot; human; loading ...; fig 1c
Cell Signaling Technology ERBB3 antibody (Cell Signaling, 4791) was used in western blot on human samples (fig 1c). J Biol Chem (2019) ncbi
rabbit monoclonal (21D3)
  • other; human; loading ...; fig 4c
Cell Signaling Technology ERBB3 antibody (Cell Signaling, 4791) was used in other on human samples (fig 4c). Cancer Cell (2018) ncbi
rabbit monoclonal (21D3)
  • reverse phase protein lysate microarray; human; loading ...; fig st6
In order to characterize the molecular identity of uterine carcinosarcomas., Cell Signaling Technology ERBB3 antibody (CST, 4791) was used in reverse phase protein lysate microarray on human samples (fig st6). Cancer Cell (2017) ncbi
rabbit monoclonal (21D3)
  • western blot; rat; 1:1000; loading ...; fig 5c
In order to explore the role of Necl4 in peripheral myelination, Cell Signaling Technology ERBB3 antibody (Cell Signaling Technologies, 4791) was used in western blot on rat samples at 1:1000 (fig 5c). J Biol Chem (2017) ncbi
rabbit monoclonal (21D3)
  • reverse phase protein lysate microarray; human; loading ...; fig 3a
In order to describe the features of 228 primary cervical cancers, Cell Signaling Technology ERBB3 antibody (Cell Signaling, 4791) was used in reverse phase protein lysate microarray on human samples (fig 3a). Nature (2017) ncbi
rabbit monoclonal (21D3)
  • western blot; human; loading ...; fig 6a, 6d
In order to study the contribution of the heregulin-1/HER3-driven pathway to hepatocellular carcinoma, Cell Signaling Technology ERBB3 antibody (Cell Signaling, 4791) was used in western blot on human samples (fig 6a, 6d). J Exp Clin Cancer Res (2016) ncbi
rabbit monoclonal (21D3)
  • western blot; human; 1:1000; loading ...; fig 3
Cell Signaling Technology ERBB3 antibody (Cell Signaling Technology, 4791) was used in western blot on human samples at 1:1000 (fig 3). Oncotarget (2016) ncbi
rabbit monoclonal (21D3)
  • immunohistochemistry - paraffin section; human; 1:50; fig 1g
Cell Signaling Technology ERBB3 antibody (Cell Signaling, 21D3) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig 1g). Oncol Lett (2016) ncbi
rabbit monoclonal (21D3)
  • immunohistochemistry - paraffin section; mouse; fig 6
Cell Signaling Technology ERBB3 antibody (Cell Signaling, 4791) was used in immunohistochemistry - paraffin section on mouse samples (fig 6). Oncotarget (2016) ncbi
rabbit monoclonal (21D3)
  • western blot; human; fig 1
Cell Signaling Technology ERBB3 antibody (Cell Signaling, 4791) was used in western blot on human samples (fig 1). Oncogenesis (2016) ncbi
rabbit monoclonal (21D3)
  • western blot; human; fig 3e
In order to determine how hepatitis C virus activates a neuregulin-driven circuit to modify surface expression of growth factor receptors of the ErbB family, Cell Signaling Technology ERBB3 antibody (Cell Signaling, 4791) was used in western blot on human samples (fig 3e). PLoS ONE (2016) ncbi
rabbit monoclonal (21D3)
  • western blot; human; fig 1
Cell Signaling Technology ERBB3 antibody (Cell Signaling Technology, 4791) was used in western blot on human samples (fig 1). Tumour Biol (2016) ncbi
rabbit monoclonal (21D3)
  • western blot; human; fig 1
In order to study how ZEB1 drives the epithelial-mesenchymal transition-related resistance to EGFR-tyrosine kinases inhibitors in non-small cell lung cancer, Cell Signaling Technology ERBB3 antibody (Cell Signaling, 4791) was used in western blot on human samples (fig 1). PLoS ONE (2016) ncbi
rabbit monoclonal (21D3)
  • immunocytochemistry; human; fig s3
  • western blot; human; fig 1
In order to study the interactions between PMCA2 and HER2 in breast cancer cells, Cell Signaling Technology ERBB3 antibody (Cell Signaling Technology, 4791) was used in immunocytochemistry on human samples (fig s3) and in western blot on human samples (fig 1). Proc Natl Acad Sci U S A (2016) ncbi
rabbit monoclonal (21D3)
  • immunohistochemistry - paraffin section; human; 1:100
In order to determine the mechanisms of resistance to the pan-HER family inhibitor AZD8931, Cell Signaling Technology ERBB3 antibody (Cell Signaling, 4791) was used in immunohistochemistry - paraffin section on human samples at 1:100. Dis Model Mech (2016) ncbi
rabbit monoclonal (21D3)
  • western blot; human; loading ...; fig 1
In order to investigate the in vitro anti-tumor activity of afatinib., Cell Signaling Technology ERBB3 antibody (Cell Signaling Technology, 4791) was used in western blot on human samples (fig 1). Target Oncol (2016) ncbi
rabbit monoclonal (21D3)
  • western blot; human; loading ...; fig 3a
Cell Signaling Technology ERBB3 antibody (Cell signaling, 4791) was used in western blot on human samples (fig 3a). Oncotarget (2016) ncbi
rabbit monoclonal (21D3)
  • western blot; human; fig 2
Cell Signaling Technology ERBB3 antibody (Cell Signaling, 21D3) was used in western blot on human samples (fig 2). Oncotarget (2016) ncbi
rabbit monoclonal (21D3)
  • western blot; human; 1:200; fig 1
In order to study anti-tumor activity of breast cancer models resistant to anti-HER2 drugs due to a dual fatty acid synthase and HER2 signaling blockade, Cell Signaling Technology ERBB3 antibody (Cell signaling, 4791) was used in western blot on human samples at 1:200 (fig 1). PLoS ONE (2015) ncbi
rabbit monoclonal (21D3)
  • western blot; human; fig 2
Cell Signaling Technology ERBB3 antibody (Cell Signaling, 4791) was used in western blot on human samples (fig 2). Oncotarget (2015) ncbi
rabbit monoclonal (21D3)
  • western blot; human
In order to study the effect of using an ADAM17 inhibitory antibody, MEDI3622, in several EGFR-dependent tumor models, Cell Signaling Technology ERBB3 antibody (Cell Signaling Technology, 4791) was used in western blot on human samples . Mol Cancer Ther (2015) ncbi
rabbit monoclonal (21D3)
  • immunohistochemistry - paraffin section; mouse; loading ...; fig 5b
  • western blot; mouse; loading ...; fig 1c
Cell Signaling Technology ERBB3 antibody (Cell Signaling Technologies, 4791) was used in immunohistochemistry - paraffin section on mouse samples (fig 5b) and in western blot on mouse samples (fig 1c). Cancer Chemother Pharmacol (2015) ncbi
rabbit monoclonal (21D3)
  • western blot; human; fig 2
In order to study human breast cancer cell lines and how Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration, Cell Signaling Technology ERBB3 antibody (Cell signaling, 21D3) was used in western blot on human samples (fig 2). Oncotarget (2015) ncbi
rabbit monoclonal (21D3)
  • western blot; human; fig 3
Cell Signaling Technology ERBB3 antibody (Cell Signaling, 4791S) was used in western blot on human samples (fig 3). Proteomics (2015) ncbi
rabbit monoclonal (21D3)
  • immunohistochemistry; human; 1:30
Cell Signaling Technology ERBB3 antibody (Cell Signaling, 21D3) was used in immunohistochemistry on human samples at 1:30. Anticancer Res (2014) ncbi
rabbit monoclonal (21D3)
  • western blot; human
Cell Signaling Technology ERBB3 antibody (Cell Signaling Technology, 4791) was used in western blot on human samples . Cancer Res (2014) ncbi
rabbit monoclonal (21D3)
  • western blot; human
In order to study mechanism of resistance to the FGFR inhibitor BGJ398 and the FGFR inhibitor ponatinib, Cell Signaling Technology ERBB3 antibody (cell signaling, 4791S) was used in western blot on human samples . Oncogene (2015) ncbi
rabbit monoclonal (21D3)
  • western blot; human; fig 1c
In order to suggest that Akt activation by ERBB3/HER2 limits the effectiveness of EGFR inhibition, Cell Signaling Technology ERBB3 antibody (Cell Signaling Technology, 4791) was used in western blot on human samples (fig 1c). Mol Cancer Ther (2014) ncbi
rabbit monoclonal (21D3)
  • western blot; human; fig 3
Cell Signaling Technology ERBB3 antibody (Cell Signaling, 4791) was used in western blot on human samples (fig 3). Genes Dev (2013) ncbi
rabbit monoclonal (21D3)
  • western blot; human
Cell Signaling Technology ERBB3 antibody (Cell Signaling Technology, 21D3) was used in western blot on human samples . Breast Cancer Res (2011) ncbi
Articles Reviewed
  1. Hegde G, de la Cruz C, Giltnane J, Crocker L, Venkatanarayan A, Schaefer G, et al. NRG1 is a critical regulator of differentiation in TP63-driven squamous cell carcinoma. elife. 2019;8: pubmed publisher
  2. Turowec J, Lau E, Wang X, Brown K, Fellouse F, Jawanda K, et al. Functional genomic characterization of a synthetic anti-HER3 antibody reveals a role for ubiquitination by RNF41 in the anti-proliferative response. J Biol Chem. 2019;294:1396-1409 pubmed publisher
  3. Ng P, Li J, Jeong K, Shao S, Chen H, Tsang Y, et al. Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell. 2018;33:450-462.e10 pubmed publisher
  4. Cherniack A, Shen H, Walter V, Stewart C, Murray B, Bowlby R, et al. Integrated Molecular Characterization of Uterine Carcinosarcoma. Cancer Cell. 2017;31:411-423 pubmed publisher
  5. Heffernan C, Jain M, Liu T, Kim H, Barretto K, Li H, et al. Nectin-like 4 Complexes with Choline Transporter-like Protein-1 and Regulates Schwann Cell Choline Homeostasis and Lipid Biogenesis in Vitro. J Biol Chem. 2017;292:4484-4498 pubmed publisher
  6. . Integrated genomic and molecular characterization of cervical cancer. Nature. 2017;543:378-384 pubmed publisher
  7. Buta C, Benabou E, Lequoy M, Régnault H, Wendum D, Meratbene F, et al. Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin. J Exp Clin Cancer Res. 2016;35:126 pubmed publisher
  8. Alver T, Lavelle T, Longva A, Øy G, Hovig E, Bøe S. MITF depletion elevates expression levels of ERBB3 receptor and its cognate ligand NRG1-beta in melanoma. Oncotarget. 2016;7:55128-55140 pubmed publisher
  9. Lattanzio R, Veschi S, Aceto G, Curia M, Cama A, De Lellis L, et al. Overexpression of PY1289-HER3 in sporadic pulmonary carcinoid from patients bearing MEN1 gene variants. Oncol Lett. 2016;12:453-458 pubmed
  10. Mancini M, Lien E, Toker A. Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis. Oncotarget. 2016;7:17301-13 pubmed publisher
  11. Meng Y, Zheng L, Yang Y, Wang H, Dong J, Wang C, et al. A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors. Oncogenesis. 2016;5:e211 pubmed publisher
  12. Stindt S, Cebula P, Albrecht U, Keitel V, Schulte Am Esch J, Knoefel W, et al. Hepatitis C Virus Activates a Neuregulin-Driven Circuit to Modify Surface Expression of Growth Factor Receptors of the ErbB Family. PLoS ONE. 2016;11:e0148711 pubmed publisher
  13. Cao K, Gong H, Qiu Z, Wen Q, Zhang B, Tang T, et al. Hepatitis B virus X protein reduces the stability of Nrdp1 to up-regulate ErbB3 in hepatocellular carcinoma cells. Tumour Biol. 2016;37:10375-82 pubmed publisher
  14. Yoshida T, Song L, Bai Y, Kinose F, Li J, Ohaegbulam K, et al. ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. PLoS ONE. 2016;11:e0147344 pubmed publisher
  15. Jeong J, VanHouten J, Dann P, Kim W, Sullivan C, Yu H, et al. PMCA2 regulates HER2 protein kinase localization and signaling and promotes HER2-mediated breast cancer. Proc Natl Acad Sci U S A. 2016;113:E282-90 pubmed publisher
  16. Creedon H, Balderstone L, Muir M, Balla J, Gómez Cuadrado L, Tracey N, et al. Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer. Dis Model Mech. 2016;9:131-40 pubmed publisher
  17. Huguet F, Fernet M, Giocanti N, Favaudon V, Larsen A. Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status. Target Oncol. 2016;11:371-81 pubmed publisher
  18. Chen J, Chen Y, Yen C, Chen W, Huang W. HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3. Oncotarget. 2016;7:473-89 pubmed publisher
  19. Safavi S, Järnum S, Vannas C, Udhane S, Jonasson E, Tomić T, et al. HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo. Oncotarget. 2016;7:433-45 pubmed publisher
  20. Blancafort A, Giró Perafita A, Oliveras G, Palomeras S, Turrado C, Campuzano Ã, et al. Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs. PLoS ONE. 2015;10:e0131241 pubmed publisher
  21. Hutchinson K, Johnson D, Johnson A, Sanchez V, Kuba M, Lu P, et al. ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. Oncotarget. 2015;6:22348-60 pubmed
  22. Rios Doria J, Sabol D, Chesebrough J, Stewart D, Xu L, Tammali R, et al. A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated Pathways. Mol Cancer Ther. 2015;14:1637-49 pubmed publisher
  23. Meneses Lorente G, Friess T, Kolm I, Hölzlwimmer G, Bader S, Meille C, et al. Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody. Cancer Chemother Pharmacol. 2015;75:837-50 pubmed publisher
  24. Momeny M, Saunus J, Marturana F, McCart Reed A, Black D, Sala G, et al. Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines. Oncotarget. 2015;6:3932-46 pubmed
  25. Blair B, Wu X, Zahari M, Mohseni M, Cidado J, Wong H, et al. A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations. Proteomics. 2015;15:318-26 pubmed publisher
  26. Cha Y, Han S, Seol H, Oh D, Im S, Bang Y, et al. Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer. Anticancer Res. 2014;34:4275-80 pubmed
  27. Kugel C, Hartsough E, Davies M, Setiady Y, Aplin A. Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor. Cancer Res. 2014;74:4122-32 pubmed publisher
  28. Wang J, Mikse O, Liao R, Li Y, Tan L, Jänne P, et al. Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells. Oncogene. 2015;34:2167-77 pubmed publisher
  29. Zhang L, Castanaro C, Luan B, Yang K, Fan L, Fairhurst J, et al. ERBB3/HER2 signaling promotes resistance to EGFR blockade in head and neck and colorectal cancer models. Mol Cancer Ther. 2014;13:1345-55 pubmed publisher
  30. Ni M, Chen Y, Fei T, Li D, Lim E, Liu X, et al. Amplitude modulation of androgen signaling by c-MYC. Genes Dev. 2013;27:734-48 pubmed publisher
  31. Lindberg K, Helguero L, Omoto Y, Gustafsson J, Haldosén L. Estrogen receptor ? represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity. Breast Cancer Res. 2011;13:R43 pubmed publisher